BFSG LLC’s Charles River Laboratories CRL Stock Holding History

BFSG LLC’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.18K	Buy	+4	New	+$1.05K	﹤0.01%	826

Other funds holding CRL

Cooke & Bieler Philadelphia, Pennsylvania $6.36B AUM 0.55% 1-Year Est. Return

Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Confluence Investment Management St. Louis, Missouri $5.97B AUM 5.11% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Lawson Kroeker Investment Management Omaha, Nebraska $360M AUM 21.88% 1-Year Est. Return

Midwest Trust Overland Park, Kansas $8.99B AUM 21.14% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

BFSG LLC's CRL Position: Q3 2026 in Review

BFSG LLC opened a new position in Charles River Laboratories (CRL) in Q3 2026: 4 shares worth $1.18K. The stake represents ﹤0.01% of the portfolio and ranks #826 among its holdings.

172 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

BFSG LLC held 4 shares of Charles River Laboratories worth $1.18K as of Q3 2026.
Charles River Laboratories was a new BFSG LLC position in Q3 2026.
Charles River Laboratories made up ﹤0.01% of BFSG LLC's portfolio in Q3 2026, its #826 holding.
172 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on BFSG LLC's 13F filing for Q3 2026, filed 30 Oct 2026.